Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials

To date, no studies have compared the new first‐line atezolizumab+bevacizumab with transarterial therapies combined with the prior standard‐of‐care, sorafenib, in patients with advanced hepatocellular carcinoma (HCC). We compared and ranked all relevant transarterial and targeted treatments competin...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Jihyun, Han, Seungbong, Kim, Ha Il, Shim, Ju Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512463/
https://www.ncbi.nlm.nih.gov/pubmed/35785525
http://dx.doi.org/10.1002/hep4.2025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512463/
https://www.ncbi.nlm.nih.gov/pubmed/35785525
http://dx.doi.org/10.1002/hep4.2025

Ejemplares similares